Johnson & Johnson vs Ryanair Holdings plc — how do they compare? Johnson & Johnson trades at $260.79 (market cap $626.09B), while Ryanair Holdings plc trades at $59.39 (market cap $29.63B). The key difference: Johnson & Johnson is far larger — about 21.1× Ryanair Holdings plc's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | RYAAY | |
|---|---|---|
Market Cap | $626.09B | $29.63B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $73.82 |
52-Week Low | $172.78 | $53.24 |
Enterprise Value | $654.37B | $26.61B |
Dividend Yield | 2.06% | 1.51% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Ryanair Holdings (RYAAY) trades at $59.41, down 0.17% with bearish technical signals despite reasonable valuations (P/E 14.37). The airline reported mixed quarterly results with Q1 2026 beating expectations but Q2 2026 missing, while maintaining strong profitability (22.41% ROE) and a solid balance sheet with $3.96B cash. Recent news highlights operational challenges from lower fares and fuel costs, alongside strategic AI partnerships.
Outlook remains cautious due to near-term headwinds from fare pressure and geopolitical risks, but long-term prospects are supported by industry consolidation potential and strong financials. Analyst consensus is bullish (62.5% Buy ratings), viewing current weakness as overdone. Key risks include fuel price volatility and competitive dynamics.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →